Navigation Links
InterMune to Present at Canaccord Adams Conference
Date:8/7/2009

BRISBANE, Calif., Aug. 7 /PRNewswire-FirstCall/ -- InterMune, Inc. (Nasdaq: ITMN) today announced that Dan Welch, Chairman, Chief Executive Officer and President of InterMune, will present at the Canaccord Adams 29th Annual Global Growth Conference in Boston on August 12, 2009 at 10:30 a.m. EDT.

To access a live audio webcast of the presentation, investors and other interested parties may log on to the investor relations page of InterMune's corporate website at www.intermune.com. The company recommends logging on to the site 15 minutes prior to the start of the presentation in order to register or download any necessary software.

About InterMune

InterMune is a biotechnology company focused on the research, development and commercialization of innovative therapies in pulmonology and hepatology. InterMune has an R&D portfolio addressing idiopathic pulmonary fibrosis (IPF) and hepatitis C virus (HCV) infections. The pulmonology portfolio includes pirfenidone for which a Phase 3 program in patients with IPF (CAPACITY) has been completed and the compound is currently in the pre-registration stage. The hepatology portfolio includes the HCV protease inhibitor compound ITMN-191 (referred to as R7227 at Roche) expected to enter Phase 2b in August of 2009 and a second-generation HCV protease inhibitor research program. For additional information about InterMune and its R&D pipeline, please visit www.intermune.com.


'/>"/>
SOURCE InterMune, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. InterMune Reports Second Quarter 2009 Financial Results and Business Highlights
2. InterMune to Release Second Quarter Financial Results on August 6
3. InterMune to Present at Goldman Sachs Healthcare Conference
4. InterMune Reports First Quarter 2009 Financial Results and Business Highlights
5. InterMune to Release First Quarter Financial Results on April 30
6. InterMune and Pharmasset to Discuss INFORM-1 Results From EASL Conference, April 25
7. InterMune to Present at Canaccord Adams Hepatitis C Conference
8. InterMune to Present at Citis 4th Annual Biotech Day
9. InterMune to Present Abstracts on HCV Protease Inhibitor ITMN-191 and HCV Development Program at the EASL Meeting
10. InterMune Reports Fourth Quarter and Full Year 2008 Financial Results and Business Highlights
11. InterMune to Release Fourth Quarter, Full Year 2008 Financial Results on February 26
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2017)... (PRWEB) , ... May 24, 2017 , ... ... systems are increasingly being developed with Wi-Fi connectivity to reduce the amount of ... room to room. In addition, compact mobile devices including infusion pumps, heart and ...
(Date:5/23/2017)... ... May 23, 2017 , ... ... unlimited source of human cardiovascular cells for research and the development of ... it possible to generate large numbers of cardiomyocytes (hPSC-CMs). Due to varying ...
(Date:5/23/2017)... PARK, CA (PRWEB) , ... May 23, 2017 , ... ... the publication of “Label-free isolation of prostate circulating tumor cells using Vortex microfluidic ... is the result of a collaboration with Dr. Dino Di Carlo and Dr. Matthew ...
(Date:5/23/2017)... ... May 23, 2017 , ... Cambridge Semantics , the leading ... year’s Bio-IT World Conference and Expo in Boston May 23-25 with a ... The Anzo Smart Data Lake is also a finalist for the Best of ...
Breaking Biology Technology:
(Date:4/5/2017)... , April 4, 2017 KEY FINDINGS ... anticipated to expand at a CAGR of 25.76% during ... diseases is the primary factor for the growth of ... report: https://www.reportbuyer.com/product/4807905/ MARKET INSIGHTS The global ... product, technology, application, and geography. The stem cell market ...
(Date:3/30/2017)... LOS ANGELES , March 30, 2017  On ... Hack the Genome hackathon at ... This exciting two-day competition will focus on developing health ... experience. Hack the Genome is ... has been tremendous. The world,s largest companies in the ...
(Date:3/29/2017)... March 29, 2017  higi, the health IT company ... North America , today announced a Series ... acquisition of EveryMove. The new investment and acquisition accelerates ... tools to transform population health activities through the collection ... higi collects and secures data today on ...
Breaking Biology News(10 mins):